x
[contact-form-7 404 "Not Found"]

Our Business

Ariana’s XAI Driven Drug Development Platform :
Accelerated Path From Design to Approval
AI Driven Knowledge Integration and Discovery Platform Aiming at Regulatory Strategy
Ariana Pharma - Img
Robust, explainable XAI integrates a broad range of clinical and multi-omic data, leading to expedited product approval
Integrating 100,000s parameters, starting with as few as 10s of patients
0
Partnerships
0B
RWE Patients Records
0
Years of experience
0M
Total Investment
We design Precision Medicine Clinical protocols


We can start our process at the pre-clinical
stage or with as few as 10 patients.

We integrate pre-clinical data, data from
past clinical trials when they exist.

Real World Evidence data from our extensive knowledge base in order to identify biomarkers and design a data enriched clinical protocol.

Image - Ariana Pharma
We collect & generate data
Ariana Pharma - Img
Through our international leading genomic sequencing laboratory partners, we manage the process of acquiring multi-omic data (DNA, RNA, Gut micro biota, single cell RNA expression) immune profiling (FACS) etc. data. We enrich our design using our 160 Million+ Real World Evidence data, including synthetic control arms. The challenge is to analyze and integrate these datasets of diverse patient attributes into logical and actionable “signatures” that support your drug development decisions. Using our KEM® (Knowledge, Extraction, Management) technology, Ariana offers a unique and validated approach to data analysis that guarantees you learn everything you want to know from your data. By working with Ariana, you save money, save time, accelerate your development timelines and preserve patent life. Integrating 100.000s parameters : Robust, eXplainable XAI used to integrate a broad range of clinical and multi-omic data towards precision medicine
Integrate and discover with our XAI Technology​
Using our KEM® Al platform and combined analysis,
we identify:

• Optimal dose

• Companion biomarkers and best responders end-points and surrogate endpoints

• Synergistic drug combinations

• Novel indications
Ariana Pharma - Img
Regulatory Strategy
Ariana Pharma - Img

Benefiting from over 10 years of close interactions with the FDA,
we transform findings from the KEM® platform into optimal regulatory strategies for accelerated approval

KEM® Technology validated by a large number of partners
Ariana Partners
Recent Articles

Latest Press Release​s

Recent Posts

25Nov

Ariana reaffirms its position on drug development and publishes its new manifesto.

by Antonin Blandin,   0 Comments

We all share the same challenge: finding the right therapy for the rig...

Read More
Recent Posts

21Nov

Ariana Pharma enters a new era with Dr. Pascale Bouillé taking the helm of the company.

by Antonin Blandin,   0 Comments

Pascale Bouillé is the CEO of Ariana Pharma, where she leverages her ...

Read More
Precision Medicine Recent Posts

30Oct

CorpusAnalytiX and Ariana Pharma Announce Collaborative Alliance to Accelerate AI-Driven Drug Development

by Antonin Blandin,   0 Comments

Collaboration connects CorpusAnalytiX’s diverse healthcare data mark...

Read More